Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, Keiran SM, Fedorenko, Inna V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905349/
https://www.ncbi.nlm.nih.gov/pubmed/27308505
http://dx.doi.org/10.1080/23723556.2015.1008291
_version_ 1782437252044947456
author Smalley, Keiran SM
Fedorenko, Inna V
author_facet Smalley, Keiran SM
Fedorenko, Inna V
author_sort Smalley, Keiran SM
collection PubMed
description Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling.
format Online
Article
Text
id pubmed-4905349
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053492016-06-15 Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma Smalley, Keiran SM Fedorenko, Inna V Mol Cell Oncol Author's View Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling. Taylor & Francis 2015-03-19 /pmc/articles/PMC4905349/ /pubmed/27308505 http://dx.doi.org/10.1080/23723556.2015.1008291 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Smalley, Keiran SM
Fedorenko, Inna V
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title_full Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title_fullStr Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title_full_unstemmed Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title_short Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
title_sort inhibition of braf and braf+mek drives a metastatic switch in melanoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905349/
https://www.ncbi.nlm.nih.gov/pubmed/27308505
http://dx.doi.org/10.1080/23723556.2015.1008291
work_keys_str_mv AT smalleykeiransm inhibitionofbrafandbrafmekdrivesametastaticswitchinmelanoma
AT fedorenkoinnav inhibitionofbrafandbrafmekdrivesametastaticswitchinmelanoma

Ejemplares similares